nach oben

Annals of Hematology

Erschienen in:

20.02.2023 | Original Article

Prognostic value of interim ¹⁸F-FDG PET/CT in adult follicular lymphoma treated with R-CHOP

verfasst von: Na Sun, Wenli Qiao, Yan Xing, Taisong Wang, Jinhua Zhao

Erschienen in: Annals of Hematology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The prognostic value of interim ¹⁸F-FDG PET/CT (I-PET) for follicular lymphoma (FL) is controversial, and may be related to the lack of strict standards in terms of age, chemotherapy regimen, and evaluation criteria in previous studies. This study aimed to investigate the prognostic value of I-PET in adult FL patients treated with R-CHOP.

Methods

I-PET was performed in 30 adult FL patients after treatment with 3–5 cycles of R-CHOP. PET/CT images were assessed using the Deauville 5-point scale (D-5PS) criteria. Baseline PET/CT (B-PET) was performed in 24 of the patients with FL before treatment. The PET/CT image parameters, such as the SUVmax, TLG, and tMTV, were recorded. The prognostic values of sex, age, grade, Ann Arbor stage, LDH level, and I-PET were evaluated.

Results

Kaplan-Meier analysis and Cox regression showed that sex, age, grade, Ann Arbor stage, LDH, and I-PET using the D-5PS criteria could not predict the PFS of adult patients with FL treated with R-CHOP (P>0.05). ROC curve analysis evaluated the predictive values of SUVmax, TLG, and tMTV in B-PET and I-PET and showed that none of them was predictive of PFS in adult FL patients (P>0.05). However, the variation in SUVmax (∆SUVmax) was predictive of PFS in adult FL patients (AUC=0.83, P=0.040), and the cutoff threshold was 4.85.

Conclusions

I-PET using the D-5PS criteria cannot predict the PFS of adult FL patients treated with R-CHOP. However, the ∆SUVmax between B-PET and I-PET is applicable for the prognosis of adult patients with FL.

Hanel W, Epperla N (2021) Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. J Hematol Oncol 14(1):104CrossRefPubMedPubMedCentral

Cartron G, Trotman J (2022) Time for an individualized approach to first-line management of follicular lymphoma. Haematologica 107(1):7–18. https://doi.org/10.3324/haematol.2021.278766CrossRefPubMedPubMedCentral

Carbone A, Roulland S, Gloghini A et al (2019) Follicular lymphoma. Nat Rev Dis Primers 5(1):83CrossRefPubMed

Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569CrossRefPubMedPubMedCentral

Barraclough A, Bishton M, Cheah CY et al (2021) The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. Br J Haematol 195(1):15–24. https://doi.org/10.1111/bjh.17404CrossRefPubMed

Imber BS, Chau K, Goldberg E et al (2020) Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy. Leuk Lymphoma 61(6):1500–1503. https://doi.org/10.1080/10428194.2020.1716222CrossRefPubMedPubMedCentral

Juweid ME, Mueller M, Alhouri A et al (2021) Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: an update. Cancer 127(20):3727–3741. https://doi.org/10.1002/cncr.33772CrossRefPubMed

Mokrane FZ, Chen A, Schwartz LH et al (2020) Performance of CT compared with 18F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory Hodgkin lymphoma. Radiology 295(3):651–661. https://doi.org/10.1148/radiol.2020192056CrossRefPubMed

Gallamini A, Kurlapski M, Zaucha JM (2021) FDG-PET/CT for the management of post-chemotherapy residual mass in Hodgkin lymphoma. Cancers (Basel) 13(16):3952. https://doi.org/10.3390/cancers13163952CrossRefPubMed

10.

Aide N, Fruchart C, Nganoa C et al (2020) Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol 30(8):4623–4632CrossRefPubMed

11.

Aldin A, Umlauff L, Estcourt LJ et al (2020) Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev 1(1):CD012643. https://doi.org/10.1002/14651858.CD012643.pub3CrossRefPubMed

12.

Rekowski J, Hüttmann A, Schmitz C et al (2021) Interim PET evaluation in diffuse large B-Cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the ΔSUVmax method. J Nucl Med 62(1):37–42. https://doi.org/10.2967/jnumed.120.244145CrossRefPubMed

13.

Kurch L, Hüttmann A, Georgi TW et al (2021) Interim PET in diffuse large B-cell lymphoma. J Nucl Med 62(8):1068–1074. https://doi.org/10.2967/jnumed.120.255034CrossRefPubMed

14.

Qin W, Jiang X, You J et al (2021) Deauville score evaluation of interim PET/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging 48(11):3347–3350CrossRefPubMed

15.

Eertink JJ, Pfaehler EAG, Wiegers SE et al (2022) Quantitative radiomics features in diffuse large B-cell lymphoma: does segmentation method matter? J Nucl Med 63(3):389–395. https://doi.org/10.2967/jnumed.121.262117CrossRefPubMedPubMedCentral

16.

Genta S, Ghilardi G, Cascione L et al (2022) Integration of baseline metabolic parameters and mutational profiles predicts long-term response to first-line therapy in DLBCL patients: a post hoc analysis of the SAKK38/07 Study. Cancers (Basel) 14(4):1018. https://doi.org/10.3390/cancers14041018CrossRefPubMed

17.

Kostakoglu L, Mattiello F, Martelli M et al (2022) Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica 107(7):1633–1642. https://doi.org/10.3324/haematol.2021.278663CrossRefPubMed

18.

Díaz-Silván A, Otón-Sánchez LF, Caresia-Aróztegui AP et al (2022) Clinical application of [18F]FDG PET/CT in follicular lymphoma. Rev Esp Med Nucl Imagen Mol (Engl Ed) 41(3):202–212. https://doi.org/10.1016/j.remnie.2022.03.002CrossRefPubMed

19.

Lo AC, James LP, Prica A et al (2022) PET-based staging is cost-effective in early-stage follicular lymphoma. J Nucl Med 63(4):543–548. https://doi.org/10.2967/jnumed.121.262324CrossRefPubMedPubMedCentral

20.

Trotman J, Pettitt AR (2022) Is it time for PET-guided therapy in follicular lymphoma? Blood 139(11):1631–1641. https://doi.org/10.1182/blood.2020008243CrossRefPubMed

21.

Boo SH, Joo HO, Kwon SJ et al (2019) Predictive value of interim and end-of-therapy 18F-FDG PET/CT in patients with follicular lymphoma. Nucl Med Mol Imaging 53(4):263–269CrossRefPubMedPubMedCentral

22.

Liang JH, Zhang YP, Xia J et al (2019) Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma. Cancer Res Treat 51(4):1479–1487. https://doi.org/10.4143/crt.2018.649CrossRefPubMedPubMedCentral

23.

Zhou Y, Zhao Z, Li J et al (2019) Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma. Cancer Manag. Res. 11:6871–6885. https://doi.org/10.2147/CMAR.S216445CrossRefPubMedPubMedCentral

24.

Lu Z, Lin M, Downe P et al (2014) The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med 28(8):805–811CrossRefPubMed

25.

Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37(1):181–200CrossRefPubMed

26.

Welaya K, Casulo C (2019) Follicular lymphoma: redefining prognosis, current treatment options, and unmet needs. Hematol Oncol Clin North Am 33(4):627–638. https://doi.org/10.1016/j.hoc.2019.03.003CrossRefPubMed

27.

Cerhan JR (2020) Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am 34(4):631–646. https://doi.org/10.1016/j.hoc.2020.02.001CrossRefPubMedPubMedCentral

28.

Shirley MH, Sayeed S, Barnes I et al (2013) Incidence of haematological malignancies by ethnic group in England, 2001-7. Br. J. Haematol. 163(4):465–477. https://doi.org/10.1111/bjh.12562CrossRefPubMed

29.

Mozas P, Rivero A, López-Guillermo A (2021) Past, present and future of prognostic scores in follicular lymphoma. Blood Rev 50:100865. https://doi.org/10.1016/j.blre.2021.100865CrossRefPubMed

30.

Jelicic J, Stauffer Larsen T, Bukumiric Z et al (2021) The clinical applicability of current prognostic models in follicular lymphoma: a systematic review. Crit Rev Oncol Hematol 164:103418. https://doi.org/10.1016/j.critrevonc.2021.103418CrossRefPubMed

31.

Dreyling M, Ghielmini M, Rule S et al (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):298–308. https://doi.org/10.1016/j.annonc.2020.11.008CrossRefPubMed

32.

Tatsumi M, Isohashi K, Matsunaga K et al (2019) Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol 24(10):1292–1300CrossRefPubMed

33.

Casulo C (2021) Follicular lymphoma: is there an optimal way to define risk? Hematology Am Soc Hematol Educ Program 2021(1):313–319. https://doi.org/10.1182/hematology.2021000264CrossRefPubMedPubMedCentral

34.

Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95(3):316–327. https://doi.org/10.1002/ajh.25696CrossRefPubMed

35.

Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37(31):2815–2824CrossRefPubMedPubMedCentral

Titel: Prognostic value of interim 18F-FDG PET/CT in adult follicular lymphoma treated with R-CHOP
verfasst von: Na Sun
Wenli Qiao
Yan Xing
Taisong Wang
Jinhua Zhao
Publikationsdatum: 20.02.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 4/2023
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05138-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Value of the FDP/FIB ratio in predicting early severe bleeding events in patients with newly diagnosed acute promyelocytic leukemia

Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience

Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma

Pain: a neglected symptom in hemophilia

Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample Database